Biosimilars Forum Executive Director Juliana Reed to Speak at Evolution of Biosimilars Development Workshop
Reed will outline the current state of the biosimilars industry and offer solutions to increase access to lower-cost biosimilars
Juliana Reed, executive director of the Biosimilars Forum, will speak at the DIA Evolution of Biosimilar Development Workshop on May 21, 2025. Reed will discuss the current state of the biosimilars industry, highlighting the need for Americans to have increased access to lower-cost biosimilars.
The U.S. healthcare system could save an additional $189 billion on top of savings generated by biosimilars already on the market or expected to enter in the next ten years.
“The biosimilars industry has never been more important to helping lower the cost of prescription medicines,” Reed said. “Many Americans cannot afford their prescription drugs, and the PBM Monopoly continues to force high-cost, high-rebate medicines on them. Biosimilars are the free-market competition solution to lowering prescription drug prices for Americans.”
Reed will also address how regulatory bodies can help streamline the development of biosimilars.
Prices continue to increase for biologic drugs. These medications represented 46% of U.S. prescription drug spending in 2022, despite only making up 3% of prescriptions. For context, the U.S. spent $568 billion on pharmaceuticals in 2021—and $260 billion went toward biologics. With lower-cost biosimilars available, this is an affordability crisis for Americans that can easily be addressed.
In 2023, the U.S. healthcare system saved $12.4 billion from biosimilars alone. This contributed to a cumulative total of $56 billion in savings from biosimilars—compared to what spending would have been without biosimilars—since 2015.
About the DIA Conference
The 2025 DIA Evolution of Biosimilars Development Workshop: Evaluating What We Have Learned and Where We Are Headed, taking place May 20-21, 2025, will bring together global experts from regulatory agencies, industry, and advocacy organizations to discuss recent advances in biosimilar regulatory science and development paradigms. This two-day event will feature sessions on global regulatory convergence, innovations in analytical technologies, and critical manufacturing considerations. Through presentations, panel discussions, and workshops, attendees will engage with case studies and explore novel pathways emerging worldwide to make biosimilars more accessible and cost-effective. Registration information is available here.
About the Biosimilars Forum The Biosimilars Forum work to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines and improving health care. The Biosimilars Forum provides evidence-based information to inform and support public policies that encourage awareness, access, and adoption of biosimilars. For more information on the Biosimilars Forum’s work to increase access to lower-cost biosimilars, visit biosimilarsforum.org.